Abiopharma

News list

Malzahn Craig 🟢 acquired 101.2K shares (1 derivative) of REGENXBIO Inc. (RGNX) at $14.18 Transaction Date: Jan 06, 2026 | Filing ID: 000003

Full text

News bot Jan. 8, 2026, 9:45 p.m.
🔍 Malzahn Craig (Executive)

Company: REGENXBIO Inc. (RGNX)

Report Date: 2026-01-06
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 101,249
Detailed Transactions and Holdings:
- Acquired 65,847 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: A | equity_swap_involved: false | shares_owned_after: 82,194.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 35,402 shares of Stock Options (Right to buy) at $14.18 per share (Derivative)
  Date: 2026-01-06 | Code: A | Expires: 2036-01-06 | equity_swap_involved: false | shares_owned_after: 35,402.00 | transaction_form_type: 4 | Footnotes: F2
Footnotes:
- F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.
- F2: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.